These presentations can also be viewed as a CME/CE course for credits. To take this course and earn CME/CE credits – Click Here!
Click the links below to view our presentations:
Program Overview and Objectives
Stephen Nimer, MD
New WHO Classification of MDS
Robert Hasserjian, MD
Integrating Molecular Findings into the Diagnosis and Prognosis of MDS
Rafael Bejar, MD, PhD
Recent Insights into Therapy-related MDS
Richard Larson, MD
Emerging Immune-related Therapies in MDS/AML
Daniel T. Starczynowski
New clinical classification of MDS, as well as the evaluation of the implications of molecular mutations, have generated valuable advances for aiding management of patients with this disease. These recent findings will be discussed during this program. The unique nature of treatment-related MDS as a specific subset of MDS will be also be reviewed. Given the understanding of immunologic abnormalities in MDS, therapeutic interventions using immune checkpoint inhibitors and T-cell based therapies will add to this discussion, as will a number of the novel treatments using biologic targeted approaches for anemias and higher risk patients.
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
Upon completion of the educational activity, participants should be able to:
University of California, San Diego
Moores Cancer Center
La Jolla, California
Massachusetts General Hospital
Harvard Medical School
University of Chicago
University Hospital Carl Gustav Carus
Cincinnati Children’s Hospital Medical Center